Portal de Periódicos da CAPES

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

2010; Lippincott Williams & Wilkins; Volume: 24; Issue: 11 Linguagem: Inglês

10.1097/qad.0b013e32833ad8b4

1473-5571

Marisa Tungsiripat, Douglas Kitch, Marshall J. Glesby, Samir K. Gupta, John W. Mellors, Laura Moran, Lynne Jones, Beverly Alston‐Smith, James F. Rooney, Judith A. Aberg,

HIV Research and Treatment

Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.